Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Obstructive Sleep Apnea
Type
Interventional
Phase
Phase 4
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The researchers will do a trial of spironolactone in 30 obstructive sleep apnea (OSA) patients with cardiovascular disease who are non-adherent with Positive Airway Pressure (PAP) therapy.Masking: Double (Participant, Investigator)Masking Description: Both groups will receive treatment as usual for obstructive sleep apnea. Spironolactone and placebo will be prescribed by one of the study physicians (who will not be blinded to treatment condition ["care provider"]) .Primary Purpose: Supportive Care

Participation Requirements

Age
Between 18 years and 85 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04205136
Collaborators
Not Provided
Investigators
Principal Investigator: Louise O'Brien, PhD University of Michigan Principal Investigator: Bertram Pitt, MD University of Michigan Principal Investigator: J. Todd Arnedt, PhD University of Michigan